RxDoctor Payments Data

Adeleye Edon, DO

Nephrology · London, OHNPI 1306105804

Payments from drug & device makers

$494in general payments, 2019–2025

Across 29 payments — averaging $17.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$80
  • Bayer$65
  • Renalytix AI, Inc.$62
  • AstraZeneca$44
  • Calliditas Therapeutics US Inc.$38
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$38
  • plus $168 from 9 others

What the payments were for

  • Food & beverage$47195%
  • Education$235%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$494 in reported general payments places this provider in the 30th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio

Medicare billing

Part B allowed, 2024
$161,279
Medicare patients
355
Services billed
1,497

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tolvaptan42$123,154
FarxigaDapagliflozin Propanediol59$65,949
LokelmaSodium Zirconium Cyclosilicate70$50,827
KerendiaFinerenone37$32,664
JardianceEmpagliflozin16$9,150
AuryxiaFerric Citrate12$8,217
SpsSodium Polystyrene Sulfon/Sorb14$5,343
Hydralazine Hcl185$2,471
Valsartan123$2,390
Sevelamer Carbonate20$1,981
Candesartan Cilexetil38$1,655
Potassium Chloride93$1,544
Nifedipine ErNifedipine65$1,486
Olmesartan Medoxomil63$1,433
Ropinirole Hcl16$1,352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka Pharmaceutical Development & Commercialization, Inc.Tolvaptan$12$123,15442 claims
AstraZenecaFarxiga, Lokelma$44$116,776129 claims
BayerKerendia$65$32,66437 claims
Boehringer IngelheimJardiance$22$9,15016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 450 nephrology providers in Ohio.

Other nephrology in London

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →